These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 7765187)

  • 1. Eosinophilia-myalgia syndrome and tryptophan production: a cautionary tale.
    Mayeno AN; Gleich GJ
    Trends Biotechnol; 1994 Sep; 12(9):346-52. PubMed ID: 7765187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia.
    Silver RM
    Curr Opin Rheumatol; 1992 Dec; 4(6):851-6. PubMed ID: 1457280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use.
    Belongia EA; Hedberg CW; Gleich GJ; White KE; Mayeno AN; Loegering DA; Dunnette SL; Pirie PL; MacDonald KL; Osterholm MT
    N Engl J Med; 1990 Aug; 323(6):357-65. PubMed ID: 2370887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Eosinophilia myalgia syndrome (EMS) caused by L-tryptophan product and toxic oil syndrome (TOS) caused by denatured rape-seed oil].
    Maitani T; Saitoh H
    Shokuhin Eiseigaku Zasshi; 2009 Dec; 50(6):279-91. PubMed ID: 20065617
    [No Abstract]   [Full Text] [Related]  

  • 5. 1995 Bailey K. Ashford lecture. Public health lessons from two catastrophic epidemics: the toxic oil syndrome and the eosinophilia-myalgia syndrome.
    James TN
    P R Health Sci J; 1996 Mar; 15(1):45-8. PubMed ID: 8744866
    [No Abstract]   [Full Text] [Related]  

  • 6. 3-(Phenylamino)alanine, a novel aniline-derived amino acid associated with the eosinophilia-myalgia syndrome: a link to the toxic oil syndrome?
    Mayeno AN; Belongia EA; Lin F; Lundy SK; Gleich GJ
    Mayo Clin Proc; 1992 Dec; 67(12):1134-9. PubMed ID: 1469924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Of faddism, toxic oil, and scleroderma.
    Berry CL
    J Pathol; 1993 Aug; 170(4):419-20. PubMed ID: 8410491
    [No Abstract]   [Full Text] [Related]  

  • 8. [Eosinophilia-myalgia: new syndrome].
    Szechiński J; Borysewicz K
    Postepy Hig Med Dosw; 1992; 46(3):319-25. PubMed ID: 1369828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid HPLC screening method for contaminants found in implicated L-tryptophan associated with eosinophilia myalgia syndrome and adulterated rapeseed oil associated with toxic oil syndrome.
    Williamson BL; Tomlinson AJ; Hurth KM; Posada de la Paz M; Gleich GJ; Naylor S
    Biomed Chromatogr; 1998; 12(5):255-61. PubMed ID: 9787895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia.
    Bolster MB; Silver RM
    Curr Opin Rheumatol; 1994 Nov; 6(6):642-9. PubMed ID: 7865387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The eosinophilia-myalgia syndrome and tryptophan.
    Belongia EA; Mayeno AN; Osterholm MT
    Annu Rev Nutr; 1992; 12():235-56. PubMed ID: 1503805
    [No Abstract]   [Full Text] [Related]  

  • 12. Eosinophilia-myalgia syndrome in patients ingesting a single source of L-tryptophan.
    Henning KJ; Jean-Baptiste E; Singh T; Hill RH; Friedman SM
    J Rheumatol; 1993 Feb; 20(2):273-8. PubMed ID: 8474064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural characterization of contaminants found in commercial preparations of melatonin: similarities to case-related compounds from L-tryptophan associated with eosinophilia-myalgia syndrome.
    Williamson BL; Tomlinson AJ; Mishra PK; Gleich GJ; Naylor S
    Chem Res Toxicol; 1998 Mar; 11(3):234-40. PubMed ID: 9544622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eosinophilia-myalgia syndrome associated with exposure to tryptophan from a single manufacturer.
    Slutsker L; Hoesly FC; Miller L; Williams LP; Watson JC; Fleming DW
    JAMA; 1990 Jul; 264(2):213-7. PubMed ID: 2355442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tryptophan toxicity: a pharmacoepidemiologic review of eosinophilia-myalgia syndrome.
    Milburn DS; Myers CW
    DICP; 1991 Nov; 25(11):1259-62. PubMed ID: 1763543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AHR activation by tryptophan--pathogenic hallmark of Th17-mediated inflammation in eosinophilic fasciitis, eosinophilia-myalgia-syndrome and toxic oil syndrome?
    Rieber N; Belohradsky BH
    Immunol Lett; 2010 Feb; 128(2):154-5. PubMed ID: 19941898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tryptophan contaminants associated with eosinophilia-myalgia syndrome. The Eosinophilia-Myalgia Studies of Oregon, New York and New Mexico.
    Philen RM; Hill RH; Flanders WD; Caudill SP; Needham L; Sewell L; Sampson EJ; Falk H; Kilbourne EM
    Am J Epidemiol; 1993 Aug; 138(3):154-9. PubMed ID: 8356958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and formation of an EMS correlated contaminant in biotechnologically manufactured L-tryptophan.
    Müller B; Pacholski C; Simat T; Steinhart H
    Adv Exp Med Biol; 1999; 467():481-6. PubMed ID: 10721091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. L-tryptophan and the eosinophilia-myalgia syndrome.
    Drug Ther Bull; 1990 May; 28(10):37-8. PubMed ID: 2131206
    [No Abstract]   [Full Text] [Related]  

  • 20. L-tryptophan: eosinophilia-myalgia syndrome.
    D'Arcy PF
    Adverse Drug React Toxicol Rev; 1995; 14(1):37-43. PubMed ID: 7612781
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.